Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by founding CEO Tassos Gianakakos and fellow former MyoKardia ...

Medera announced that its wholly owned preclinical subsidiary for disease modelling and drug discovery, Novoheart, has entered into a partnership with Curi Bio. This strategic collaboration integrates ...

In a new study published in the European Heart Journal, researchers reported the successful development and validation of a medical artificial intelligence (AI) model that screens for cardiac ...

Recent advances in cardiovascular research increasingly recognize the gut microbiome as a pivotal factor influencing cardiovascular disease (CVD) pathogenesis and treatment outcomes. The intricate ...

Researchers at Indiana University and Wuhan University in China have unveiled a groundbreaking chemical process that could streamline the development of pharmaceutical compounds, chemical building ...

This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...

A recent study shows that computer algorithms can be used to find molecules that can be developed into anti-inflammatory drugs. In the article, the researchers also describe how the same strategy can ...

Drug discovery has traditionally been slow and expensive, often taking decades and costing manufacturers billions. Traditional methods, while advancing, are hitting limits in tackling the complexities ...

Heart disease remains the leading cause of death worldwide, yet progress in understanding and treating cardiac disorders is limited by the shortcomings of existing experimental models. Traditional ...

Millions of older adults already take inexpensive blood-pressure pills every day, and a growing body of research suggests ...